Reviva Pharmaceuticals CMO Marc Cantillon resigns effective July 5, 2022

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Marc Cantillon resigns as Chief Medical Officer effective July 5, 2022, to pursue other opportunities.
Resignation not due to disagreements with company operations, policies, or practices.
Company has commenced search for new clinical management; will use independent consultants in the interim.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marc Cantillon

Chief Medical Officer

RVPH · REVIVA PHARMACEUTICALS HOLDINGS, INC.

Effective: 2022-07-05
Filed: June 27, 2022, 7:59 PM ET

On June 23, 2022, Marc Cantillon, the Chief Medical Officer of Reviva Pharmaceuticals Holdings, Inc. (the “Company”), notified the Company that he will resign as Chief Medical Officer of the Company effective as of July 5, 2022 to pursue additional opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Marc Cantillon resigned as Chief Medical Officer at REVIVA PHARMACEUTICALS HOLDINGS, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On June 23, 2022, Marc Cantillon, the Chief Medical Officer of Reviva Pharmaceuticals Holdings, Inc. (the “Company”), notified the Company that he will resign as Chief Medical Officer of the Company effective as of July 5, 2022 to pursue additional opportunities.

View on SEC.gov

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-015928

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.